Home » Stocks » ALT

Altimmune, Inc. (ALT)

Stock Price: $8.88 USD -0.37 (-4.00%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $8.87 -0.01 (-0.11%) Jul 23, 7:54 PM
Market Cap 340.96M
Revenue (ttm) 6.81M
Net Income (ttm) -60.02M
Shares Out 38.91M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $8.88
Previous Close $9.25
Change ($) -0.37
Change (%) -4.00%
Day's Open 9.26
Day's Range 8.84 - 9.29
Day's Volume 737,864
52-Week Range 7.80 - 29.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.

Other stocks mentioned: GOOGL, JNJ, WBA
3 weeks ago - Schaeffers Research

The company halts development on both a COVID-19 vaccine and a drug targeting the disease.

3 weeks ago - The Motley Fool

Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the development ...

3 weeks ago - Schaeffers Research

Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 1/2 trial for T-COVID, single-d...

3 weeks ago - Benzinga

The following stocks are attracting high retail-investor interest on social media early Wednesday.  SoFi Technologies Inc (NASDAQ:SOFI): The personal finance company continues to dominate r/WallStreetBe...

Other stocks mentioned: CLOV, SOFI
3 weeks ago - Benzinga

GAITHERSBURG, Md., June 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the pr...

3 weeks ago - GlobeNewsWire

Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...

1 month ago - Zacks Investment Research

Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was a...

1 month ago - Benzinga

An experimental new weight loss drug produced compelling data in an early stage clinical trial.

1 month ago - The Motley Fool

Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study is currently being condu...

1 month ago - Benzinga

GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its...

1 month ago - GlobeNewsWire

Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine neutralized the COVID-19 B.1.351 variant th...

1 month ago - Benzinga

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June

2 months ago - GlobeNewsWire

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial result...

2 months ago - GlobeNewsWire

Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The resul...

2 months ago - Benzinga

Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2

2 months ago - GlobeNewsWire

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Alternus Energy Group PLC (NOTC:ALT) named industry veteran Gary Swan as its chief technical officer, as the fast-growing independent power producer expands its footprint across Europe.  “Swan will join...

3 months ago - Proactive Investors

Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, announced the recent issuance of €9 million convertible notes lead by AVG Group Sarl, a Luxembourg-based a...

3 months ago - Proactive Investors

10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX)  presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...

Other stocks mentioned: AUIAF, AURQF, AUSAF, BABYF, CAAOF, CRTPF, GNPX ...
3 months ago - Proactive Investors

The short answer: It depends.

3 months ago - The Motley Fool

Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose...

3 months ago - Benzinga

GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine...

3 months ago - GlobeNewsWire

Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, has announced the completion of the acquisition of two additional solar parks in Romania from Renesola Pow...

3 months ago - Proactive Investors

Metered Multidose Device Allows for Convenient and Cost-effective Vaccination Metered Multidose Device Allows for Convenient and Cost-effective Vaccination

4 months ago - GlobeNewsWire

If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.

4 months ago - The Motley Fool

Altimmune Inc. (NASDAQ: ALT) is making headway in the fight against COVID-19 after the firm announced additional preclinical data in regards to its single-dose intranasal vaccine candidate, AdCOVID.

4 months ago - 24/7 Wall Street

Altimmune Inc (NASDAQ: ALT) has reported additional preclinical data for COVID-19 vaccine candidate, AdCOVID. The data showed that a single intranasal dose of AdCOVID provided 100% protection against th...

4 months ago - Benzinga

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...

Other stocks mentioned: CFRX, EVOK, NVAX
4 months ago - Benzinga

Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under t...

4 months ago - Benzinga

Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commerci...

4 months ago - GlobeNewsWire

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...

4 months ago - Proactive Investors

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...

4 months ago - Proactive Investors

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a...

4 months ago - GlobeNewsWire

Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is particul...

4 months ago - Proactive Investors

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Nasal spray may offer room temperature distribution that could reduce logistical  challenges for healthcare systems and providers

4 months ago - GlobeNewsWire

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results o...

5 months ago - GlobeNewsWire

The company's COVID-19 program is moving ahead.

5 months ago - The Motley Fool

Altimmune Inc (NASDAQ: ALT) shares are advancing following an update on its coronavirus vaccine program. What Happened: Maryland-based Altimmune said the FDA has cleared its investigational new drug app...

5 months ago - Benzinga

Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free, ...

5 months ago - GlobeNewsWire

No kidding around ... here's how they truly can.

Other stocks mentioned: JUSHF, VXRT
6 months ago - The Motley Fool

New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are ad...

6 months ago - Newsfile Corp

Transport and storage of their potential vaccines would be a piece of cake.

Other stocks mentioned: VXRT
6 months ago - The Motley Fool

This biotech just might have what it takes.

6 months ago - The Motley Fool

They're risky but could deliver huge returns in the new year.

Other stocks mentioned: NVAX, VXRT
6 months ago - The Motley Fool

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

6 months ago - Zacks Investment Research

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune...

Other stocks mentioned: BCDA, INCY
6 months ago - Benzinga

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that i... [Read more...]

Industry
Biotechnology
CEO
Vipin Garg
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
ALT
Full Company Profile

Financial Performance

In 2020, Altimmune's revenue was $8.19 million, an increase of 41.09% compared to the previous year's $5.80 million. Losses were -$49.04 million, 139.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 24.86, which is an increase of 179.95% from the latest price.

Price Target
$24.86
(179.95% upside)
Analyst Consensus: Strong Buy